Chronic Kidney Disease (CKD) - Disease Area - Novo Nordisk
Stay up to date with Novo Nordisk’s latest research, scientific publications, congress materials and other medical resources on chronic kidney disease (CKD).
Novo Nordisk moves chronic kidney disease drug
1 day ago · Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.
News Details - Novo Nordisk
Mar 5, 2024 · Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial. Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the ...
FDA approves Novo Nordisk’s Ozempic to treat chronic kidney disease …
Jan 28, 2025 · The Food and Drug Administration on Tuesday approved Novo Nordisk 's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular...
Effects of Semaglutide on Chronic Kidney Disease in Patients …
May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. (Funded by Novo...
Novo's Ozempic wins FDA nod to curb kidney disease risks
Jan 28, 2025 · Novo Nordisk's success with Ozempic in diabetes and kidney disease patients isn't enough for investors Novo estimates that CKD affects some 37 million adults in the U.S., with that number likely ...
FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to …
Plainsboro, N.J., January 28, 2025 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic ® to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD). 1 This approval, along with its existing indications for ...
New FDA Approval Adds Chronic Kidney Disease to Ozempic’s …
Jan 29, 2025 · Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these...
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease …
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.
FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD
Jan 28, 2025 · The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular ...